Q4 2024 Earnings Call Transcript March 27, 2025 ADC Therapeutics SA beats earnings expectations. Reported EPS is $-0.29, ...

Discover key insights from ADC Therapeutics' Q4 2024 earnings call, including ZYNLONTA’s commercial success, clinical trial updates, and strategic ...

The EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).

Bristol Myers Squibb gets European Commission approval to expand use of CAR T cell therapy, Breyanzi for relapsed or refractory follicular lymphoma: Princeton, New Jersey Monday, ...

Princeton: Bristol Myers Squibb has announced that the European Commission (EC) has granted approval to Breyanzi ...

Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for indolent non-Hodgkin lymphoma, which was a significant recent event. During ...

The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.

About 30 percent of all non-Hodgkin lymphoma diagnoses in the United States are DLBCL. Although it is an aggressive cancer that can spread quickly, it is treatable. These can be symptoms of many ...

SUV remains the most widely used PET parameter to evaluate NHLs because it is directly associated with lymphoma aggressiveness.

Some lymphomas, called indolent lymphomas, might not even need to be treated right away because they're slow-growing. In this case, careful monitoring including imaging scans such as PET/CT is used to ...

By comparing tattoo patterns alongside cancer diagnoses, researchers found that people with tattoos have a higher occurrence of both skin cancer and lymphoma. The analysis showed that tattoos ...